Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Advances in Treatment of Isocitrate Dehydrogenase (IDH)-Wildtype Glioblastomas.

Current neurology and neuroscience reports - 1 Jun 2023

Sim Hao-Wen, Lorrey Selena, Khasraw Mustafa

Abstract excerpt

PURPOSE OF REVIEW: The management of isocitrate dehydrogenase (IDH)-wildtype glioblastomas is an area of unmet need. Despite multimodal therapy incorporating maximal safe resection, radiotherapy, and temozolomide, clinical outcomes remain poor. At disease progression or relapse, available systemic agents such as temozolomide, lomustine, and bevacizumab have limited efficacy. We review the recent advances in the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Brain Neoplasms
Share to Glioblastoma
Share to Immunotherapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Isocitrate Dehydrogenase

Share to Mutation

Share to Prognosis

Share to Temozolomide

Source

Identifiers

PMID: 37154886
DOI: 10.1007/s11910-023-01268-0

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Advances in Treatment of Isocitrate Dehydrogenase (IDH)-Wildtype Glioblastomas.PMID 37154886Read ↗

Management of glioblastoma: State of the art and future directions.Semantic proximity Read ↗

Therapies for IDH-Mutant Gliomas.Semantic proximity Read ↗

Isocitrate dehydrogenase (IDH) mutant gliomas: A Society for Neuro-Oncology (SNO) consensus review on diagnosis, management, and future directions.Semantic proximity Read ↗

Glioblastoma IDH-wildtype: An integrative review of pathophysiological mechanisms, diagnostic innovations, and emerging therapeutic modalities.Semantic proximity Read ↗

The role of vorasidenib in the treatment of isocitrate dehydrogenase-mutant glioma.Semantic proximity Read ↗

Treatment Options for IDH-Mutant Malignant Gliomas.Semantic proximity Read ↗

Current and promising treatment strategies in glioma.Semantic proximity Read ↗

Management of Adult Patients With Isocitrate Dehydrogenase-Mutant Gliomas in Australia: An Expert Position Statement From the Cooperative Trials Group for Neuro-Oncology.Semantic proximity Read ↗

Treatment of IDH-mutant glioma in the INDIGO eraSemantic proximity Read ↗

Updates in IDH-Wildtype Glioblastoma.Semantic proximity Read ↗

Multidisciplinary Management of Isocitrate Dehydrogenase-Mutated Gliomas in a Contemporary Molecularly Defined Era.Semantic proximity Read ↗

Targeting IDH1/IDH2 mutations in gliomas.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.